Cha Hyunkyung, Ryu Gwanghui, Yoo Shin Hyuk, Mo Ji-Hun
Department of Otorhinolaryngology-Head and Neck Surgery, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Republic of Korea.
Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
J Rhinol. 2023 Nov;30(3):155-160. doi: 10.18787/jr.2023.00061. Epub 2023 Nov 27.
In 2021, biologics were approved for treating chronic rhinosinusitis with nasal polyps (CRSwNP) in Korea. However, CRS is a heterogeneous disease, and its characteristics are thought to differ between Western and Korean populations. This study aimed to evaluate the experiences of members of the Korean Rhinologic Society during the first year of biologic usage for the treatment of nasal polyps.
An anonymous survey consisting of 15 items was conducted from November to December 2021. The survey included questions about participant demographics, use of biologics for treating CRSwNP, and expectations regarding the effectiveness of biologics for treating CRSwNP.
In total, 44 members participated in the survey. Approximately half of the respondents were in their 40s (50.0%) and had 5-9 years of clinical experience as otorhinolaryngologists (47.7%). The majority of participants held academic positions (95.4%). About half of them worked in Gyeonggi Province. The utilization of biologics did not differ significantly based on clinical experience (p=0.192). When asked about the factors considered for prescribing biologics, the most common reason was recurrence of polyps after surgery (87.2%). The most frequent reason for discontinuing biologics was cost (48.6%). When asked about the extent to which they expected that the availability of biologics for CRSwNP treatment would reduce endoscopic sinus surgery (ESS), 45.5% of members expected a reduction of approximately 10%-29%. In addition, 20.5% expected a reduction of 50% or more. However, 61.4% expected a reduction of less than 10% in primary ESS. In addition, most respondents (93.2%) agreed with the need for Korea-specific guidelines for biologic treatment.
There are discrepancies between the current guidelines for biologic treatment of CRSwNP and the reality of the situation, highlighting the need for the development of Korea-specific guidelines.
2021年，生物制剂在韩国被批准用于治疗伴有鼻息肉的慢性鼻-鼻窦炎（CRSwNP）。然而，CRS是一种异质性疾病，其特征在西方人群和韩国人群中被认为有所不同。本研究旨在评估韩国鼻科学会成员在使用生物制剂治疗鼻息肉的第一年中的经验。
于2021年11月至12月进行了一项包含15项内容的匿名调查。该调查包括有关参与者人口统计学、使用生物制剂治疗CRSwNP以及对生物制剂治疗CRSwNP有效性的期望等问题。
共有44名成员参与了调查。大约一半的受访者年龄在40多岁（50.0%），并且作为耳鼻喉科医生有5 - 9年的临床经验（47.7%）。大多数参与者担任学术职位（95.4%）。其中约一半在京畿道工作。生物制剂的使用情况在临床经验方面没有显著差异（p = 0.192）。当被问及开处生物制剂时考虑的因素，最常见的原因是手术后息肉复发（87.2%）。停用生物制剂最常见的原因是费用（48.6%）。当被问及他们期望生物制剂用于CRSwNP治疗能在多大程度上减少内镜鼻窦手术（ESS）时，45.5%的成员期望减少约10% - 29%。此外，20.5%的成员期望减少50%或更多。然而，61.4%的成员期望在初次ESS中减少不到10%。此外，大多数受访者（93.2%）同意需要针对韩国的生物制剂治疗指南。
目前CRSwNP生物制剂治疗指南与实际情况存在差异，凸显了制定针对韩国的指南的必要性。
